Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma [PDF]
Haematologica, 2017 The GAUDI study assessed safety and preliminary efficacy of induction therapy with obinutuzumab plus chemotherapy, followed by maintenance therapy with obinutuzumab alone, in previously untreated patients with follicular lymphoma.
Andrew Grigg +8 more
doaj +8 more sources
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial [PDF]
Haematologica, 2022 iLLUMINATE is a randomized, open-label phase III study of ibrutinib plus obinutuzumab (n=113) versus chlorambucil plus obinutuzumab (n=116) as first-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Carol Moreno +15 more
doaj +3 more sources
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways [PDF]
iScience, 2021 Summary: The anti-CD20 monoclonal antibodies rituximab and obinutuzumab differ in their mechanisms of action, with obinutuzumab evoking greater direct B cell death.
Jennifer Edelmann +10 more
doaj +3 more sources
The B cell death function of obinutuzumab-HDEL produced in plant (Nicotiana benthamiana L.) is equivalent to obinutuzumab produced in CHO cells. [PDF]
PLoS ONE, 2018 Plants have attracted attention as bio-drug production platforms because of their economical and safety benefits. The preliminary efficacy of ZMapp, a cocktail of antibodies produced in N.
Jin Won Lee +8 more
doaj +6 more sources
Obinutuzumab-induced acute thrombocytopenia: a case report and literature review [PDF]
Frontiers in OncologyBackgroundObinutuzumab, a humanized type II anti-CD20 monoclonal antibody, is widely used in the treatment of B-cell lymphomas. Thrombocytopenia typically occurs 1 to 2 weeks after administration.
Xuelin Dou +3 more
doaj +3 more sources
Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma [PDF]
Haematologica, 2016 Obinutuzumab (GA101) is a type II, glycoengineered anti-CD20 monoclonal antibody for the treatment of hematologic malignancies. Obinutuzumab has mechanisms of action that are distinct from those of rituximab, potentially translating into improved ...
Guillaume Cartron +6 more
doaj +3 more sources
Disseminated Enteroviral Infection Associated with Obinutuzumab [PDF]
Emerging Infectious Diseases, 2015 Two cases of disseminated enteroviral infection occurred in patients who received the CD20 monoclonal antibody obinutuzumab. Clinical features included hepatitis, edema, and a dermatomyositis-like syndrome.
Claire Dendle +5 more
doaj +2 more sources
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia [PDF]
Clinical Interventions in Aging, 2015 Karen Seiter, Aleksandra Mamorska-DygaDepartment of Medicine, Division of Hematology/Oncology, New York Medical College, Valhalla, NY, USA Abstract: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults in Western countries ...
Seiter K, Mamorska-Dyga A
doaj +2 more sources
Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia [PDF]
Biologics: Targets & Therapy, 2015 Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj +1 more source
Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia [PDF]
SAGE Open Medical Case Reports, 2019 Obinutuzumab is used for the treatment of chronic lymphocytic leukemia. So far there are no data of using this for retreatment in patients who have received it previously.
Sharad Khurana +7 more
doaj +2 more sources